DE69320945D1 - Antivirale nukleosidanaloge - Google Patents

Antivirale nukleosidanaloge

Info

Publication number
DE69320945D1
DE69320945D1 DE69320945T DE69320945T DE69320945D1 DE 69320945 D1 DE69320945 D1 DE 69320945D1 DE 69320945 T DE69320945 T DE 69320945T DE 69320945 T DE69320945 T DE 69320945T DE 69320945 D1 DE69320945 D1 DE 69320945D1
Authority
DE
Germany
Prior art keywords
antiviral nucleoside
nucleoside analogs
substituted
benzimidazole base
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69320945T
Other languages
English (en)
Other versions
DE69320945T2 (de
Inventor
Leroy Townsend
John Drach
Steven Good
Susan DALUGE
Michael Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
University of Michigan
Original Assignee
Wellcome Foundation Ltd
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd, University of Michigan filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of DE69320945D1 publication Critical patent/DE69320945D1/de
Publication of DE69320945T2 publication Critical patent/DE69320945T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69320945T 1992-03-09 1993-03-08 Antivirale nukleosidanaloge Expired - Fee Related DE69320945T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929205071A GB9205071D0 (en) 1992-03-09 1992-03-09 Therapeutic nucleosides
PCT/GB1993/000479 WO1993018009A1 (en) 1992-03-09 1993-03-08 Antiviral nucleoside analogues

Publications (2)

Publication Number Publication Date
DE69320945D1 true DE69320945D1 (de) 1998-10-15
DE69320945T2 DE69320945T2 (de) 1999-02-04

Family

ID=10711750

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69320945T Expired - Fee Related DE69320945T2 (de) 1992-03-09 1993-03-08 Antivirale nukleosidanaloge

Country Status (20)

Country Link
US (1) US5534535A (de)
EP (1) EP0630368B1 (de)
JP (1) JP3450854B2 (de)
KR (2) KR950700887A (de)
AT (1) ATE170846T1 (de)
AU (1) AU672597B2 (de)
CA (1) CA2131693A1 (de)
CZ (1) CZ209494A3 (de)
DE (1) DE69320945T2 (de)
DK (1) DK0630368T3 (de)
ES (1) ES2123048T3 (de)
FI (1) FI944134A (de)
GB (1) GB9205071D0 (de)
HU (1) HUT68445A (de)
IL (1) IL104976A (de)
NZ (1) NZ249554A (de)
RU (1) RU2141952C1 (de)
TW (1) TW366339B (de)
WO (1) WO1993018009A1 (de)
ZA (1) ZA931647B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9205071D0 (en) * 1992-03-09 1992-04-22 Wellcome Found Therapeutic nucleosides
GB9413724D0 (en) * 1994-07-07 1994-08-24 Wellcome Found Therapeutic nucleosides
SK29197A3 (en) * 1994-09-09 1997-10-08 Wellcome Found Antiviral nucleoside analogues containing a substituted benzimidazole base attached to a carbocyclic ring, preparation method thereof, pharmaceutical composition and use
US5811073A (en) * 1995-06-19 1998-09-22 President And Fellows Of Harvard College Method for radioisotopic detection and localization of inflammation in a host
US5912356A (en) * 1995-09-11 1999-06-15 Glaxo Wellcome Inc. Antiviral nucleoside analogues containing a substituted benzimidazole base attached to a carbocyclic ring
GB9600142D0 (en) * 1996-01-05 1996-03-06 Wellcome Found Chemical compounds
GB9600143D0 (en) 1996-01-05 1996-03-06 Wellcome Found Therapeutic compounds
DE69819695D1 (en) 1997-02-13 2003-12-18 Glaxo Group Ltd Benzimidazolderivate
SK285228B6 (sk) * 1997-05-13 2006-09-07 Lonza Ag Spôsob výroby racemického alebo opticky aktívnehoderivátu 4-(hydroxymetyl)-2-cyklopenténu a racemicky N-butyryl-1-amino-4- (hydroxymetyl)-2-cyklopentén
HUP0002224A3 (en) 1997-06-10 2003-05-28 Univ Michigan Ann Arbor Benzimidazole derivatives of antivirus activity
PL338454A1 (en) 1997-07-30 2000-11-06 Univ Michigan Lixofuranosilbenzimidazoles as antiviral agents
US6514979B1 (en) 1999-03-03 2003-02-04 University Of Maryland Biotechnology Institute Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor
GB0008939D0 (en) 2000-04-11 2000-05-31 Glaxo Group Ltd Process for preparing substituted benzimidazole compounds
US7094770B2 (en) 2000-04-13 2006-08-22 Pharmasset, Ltd. 3′-or 2′-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
MX2010001126A (es) 2007-08-02 2010-03-01 Millennium Pharm Inc Proceso para la sintesis de inhibidores de enzima de activacion de e1.
HUE025224T2 (en) 2008-04-28 2016-02-29 Kyorin Seiyaku Kk Ciklopentilakrilsav amide derivatives
US11499722B2 (en) * 2020-04-30 2022-11-15 Bsh Home Appliances Corporation Household cooking appliance having an oven door with an interior camera

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996308A (en) * 1988-03-25 1991-02-26 Merrell Dow Pharmaceuticals Inc. Derivatives with unsaturated substitutions for the 5'-hydroxymethyl group
ZA894534B (en) * 1988-06-20 1990-03-28 Merrell Dow Pharma Novel neplanocin derivatives
GB8826205D0 (en) * 1988-11-09 1988-12-14 Wellcome Found Heterocyclic compounds
GB8926417D0 (en) * 1989-11-22 1990-01-10 Wellcome Found Heterocyclic compounds
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
US5248672A (en) * 1990-11-01 1993-09-28 The Regents Of The University Of Michigan Polysubstituted benzimidazole nucleosides as antiviral agents
GB9205071D0 (en) * 1992-03-09 1992-04-22 Wellcome Found Therapeutic nucleosides

Also Published As

Publication number Publication date
EP0630368B1 (de) 1998-09-09
NZ249554A (en) 1996-05-28
ES2123048T3 (es) 1999-01-01
JP3450854B2 (ja) 2003-09-29
FI944134A0 (fi) 1994-09-08
HU9402582D0 (en) 1994-11-28
FI944134A (fi) 1994-11-07
JPH07506816A (ja) 1995-07-27
TW366339B (en) 1999-08-11
RU2141952C1 (ru) 1999-11-27
KR950700887A (ko) 1995-02-20
CZ209494A3 (en) 1995-11-15
RU94043771A (ru) 1996-08-10
AU672597B2 (en) 1996-10-10
HUT68445A (en) 1995-06-28
ZA931647B (en) 1994-09-08
AU3643293A (en) 1993-10-05
WO1993018009A1 (en) 1993-09-16
IL104976A0 (en) 1993-07-08
GB9205071D0 (en) 1992-04-22
KR970705547A (ko) 1997-10-09
IL104976A (en) 1998-10-30
EP0630368A1 (de) 1994-12-28
ATE170846T1 (de) 1998-09-15
CA2131693A1 (en) 1993-09-16
DK0630368T3 (da) 1999-06-07
DE69320945T2 (de) 1999-02-04
US5534535A (en) 1996-07-09

Similar Documents

Publication Publication Date Title
DE69320945T2 (de) Antivirale nukleosidanaloge
DK169991A (da) Antivirale forbindelser
DE3780581D1 (de) Antiviralen phosphonomethoxyalkylen-purin- und -pyrimidin-derivate.
FI20001231A (fi) 2-Deoksi-2,3-didehydro-N-asetyylineuramiinihapon johdannaisia ja niiden analogeja ja niiden käyttö antiviraalisina aineina
KR950700298A (ko) 뉴클레오시드 치료제(Therapeutic Nucleosides)
ATE63747T1 (de) Antivirale verbindungen.
DK615788A (da) Nucleosidforbindelser til anvendelse mod virale infektioner
ATE36331T1 (de) Guanin-derivate, diese enthaltende zusammensetzungen und ihre antivirale wirkung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee